<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Pain</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Pain</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1532-2149</journal-id><journal-id journal-id-type="publisher-id">EJP</journal-id><journal-title-group><journal-title>European Journal of Pain (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1090-3801</issn><issn pub-type="epub">1532-2149</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27062079</article-id><article-id pub-id-type="pmc">5071659</article-id><article-id pub-id-type="doi">10.1002/ejp.875</article-id><article-id pub-id-type="publisher-id">EJP875</article-id><article-categories><subj-group subj-group-type="overline"><subject>Short Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour&#x02010;related pain</article-title><alt-title alt-title-type="left-running-head">H.G. Kress et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="ejp875-cr-0001" contrib-type="author" corresp="yes"><name><surname>Kress</surname><given-names>H.G.</given-names></name><address><email>hans-georg.kress@meduniwien.ac.at</email></address><xref ref-type="aff" rid="ejp875-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ejp875-cr-0002" contrib-type="author"><name><surname>Koch</surname><given-names>E.D.</given-names></name><xref ref-type="aff" rid="ejp875-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ejp875-cr-0003" contrib-type="author"><name><surname>Kosturski</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="ejp875-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ejp875-cr-0004" contrib-type="author"><name><surname>Steup</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="ejp875-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ejp875-cr-0005" contrib-type="author"><name><surname>Karcher</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="ejp875-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ejp875-cr-0006" contrib-type="author"><name><surname>Dogan</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="ejp875-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ejp875-cr-0007" contrib-type="author"><name><surname>Etropolski</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="ejp875-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ejp875-cr-0008" contrib-type="author"><name><surname>Eerdekens</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="ejp875-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="ejp875-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Special Anesthesia and Pain Therapy</named-content><institution>Medical University of Vienna/AKH</institution><named-content content-type="city">Vienna</named-content><country country="AT">Austria</country></aff><aff id="ejp875-aff-0002"><label><sup>2</sup></label><institution>Gr&#x000fc;nenthal GmbH</institution><named-content content-type="city">Aachen</named-content><country country="DE">Germany</country></aff><aff id="ejp875-aff-0003"><label><sup>3</sup></label><institution>Janssen Research &#x00026; Development, LLC</institution><named-content content-type="city">Raritan</named-content><named-content content-type="country-part">NJ</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Hans G. Kress<break/>
E&#x02010;mail: <email>hans-georg.kress@meduniwien.ac.at</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><volume>20</volume><issue>9</issue><issue-id pub-id-type="doi">10.1111/ejp.2016.20.issue-9</issue-id><fpage>1513</fpage><lpage>1518</lpage><history><date date-type="accepted"><day>02</day><month>3</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 European European Pain Federation &#x02010; EFIC&#x000ae; <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. <italic>European Journal of Pain</italic> published by John Wiley &#x00026; Sons Ltd on behalf of European Pain Federation &#x02010; EFIC<sup>&#x000ae;</sup>.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EJP-20-1513.pdf"/><abstract id="ejp875-abs-0001"><title>Abstract</title><sec id="ejp875-sec-0001"><title>Background</title><p>A recent randomized&#x02010;withdrawal, active&#x02010; and placebo&#x02010;controlled, double&#x02010;blind phase 3 study showed that tapentadol prolonged release (<styled-content style="fixed-case">PR</styled-content>) was effective and well tolerated for managing moderate to severe, chronic malignant tumour&#x02010;related pain in patients who were opioid naive or dissatisfied with current treatment (<italic>Pain Physician</italic>, 2014, 17, 329&#x02013;343). This post hoc, subgroup analysis evaluated the efficacy and tolerability of tapentadol <styled-content style="fixed-case">PR</styled-content> in patients who previously received and were dissatisfied with tramadol for any reason and who had a pain intensity &#x02265;5 (11&#x02010;point numerical rating scale) before converting directly to tapentadol <styled-content style="fixed-case">PR</styled-content>.</p></sec><sec id="ejp875-sec-0002"><title>Methods</title><p>In the original study, eligible patients had been randomized (2:1) and titrated to their optimal dose of tapentadol <styled-content style="fixed-case">PR</styled-content> (100&#x02013;250&#x000a0;mg bid) or morphine sulphate&#x02010;controlled release (40&#x02013;100&#x000a0;mg bid) over 2&#x000a0;weeks. The present report focuses on results during the titration period for a subgroup of patients randomized to tapentadol <styled-content style="fixed-case">PR</styled-content> after having been on tramadol treatment prior to randomization in the study (<italic>n&#x000a0;</italic>=&#x000a0;129). Results for this subgroup are compared with results for all 338 patients who received tapentadol <styled-content style="fixed-case">PR</styled-content> during titration (overall tapentadol <styled-content style="fixed-case">PR</styled-content> group).</p></sec><sec id="ejp875-sec-0003"><title>Results</title><p>Responder rates (responders: completed titration, mean pain intensity &#x0003c;5 [0&#x02013;10 scale] and &#x02264;20&#x000a0;mg/day rescue medication during last 3&#x000a0;days) were slightly better for the tramadol/tapentadol <styled-content style="fixed-case">PR</styled-content> subgroup (69.8% [90/129]) vs. the overall tapentadol <styled-content style="fixed-case">PR</styled-content> group (63.9% [214/335]). Tolerability profiles were comparable for both groups.</p></sec><sec id="ejp875-sec-0004"><title>Conclusions</title><p>Results of this subgroup analysis indicate that patients with cancer pain could safely switch from prior treatment with the weak centrally acting analgesic tramadol directly to the strong centrally acting analgesic tapentadol <styled-content style="fixed-case">PR</styled-content>, for an improved analgesic therapy for severe pain.</p></sec><sec id="ejp875-sec-0005"><title>What does this study add?</title><p>
<list list-type="bullet" id="ejp875-list-0001"><list-item><p>Results of this post hoc analysis show that patients who had received prior tramadol therapy could switch directly to tapentadol PR, with the majority (&#x002dc;70%) experiencing improved efficacy.</p></list-item></list>
</p></sec></abstract><funding-group><award-group><funding-source>Gr&#x000fc;nenthal GmbH</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Janssen Research &#x00026; Development, LLC</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="4"/><page-count count="6"/><word-count count="4147"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>ejp875</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.5 mode:remove_FC converted:20.10.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="ejp875-ntgp-0001"><fn id="ejp875-note-0001"><p>
<bold>Funding sources</bold>
</p><p>These analyses were funded by Gr&#x000fc;nenthal GmbH and Janssen Research &#x00026; Development, LLC.</p></fn><fn id="ejp875-note-0002"><p>
<bold>Conflicts of interest</bold>
</p><p>H. G. K. has received support for consultancy services from Astellas, Bene Arzneimittel GmbH, Bial, Gr&#x000fc;nenthal GmbH, Helsinn SA, Janssen Pharmaceuticals, Linde Group, Mundipharma International Ltd., Novartis, Teva/Cephalon, Philips, IBSA Foundation and Bionorica Ethics Austria. E. D. K., and Ma. E. are employees of Gr&#x000fc;nenthal GmbH. A. S., C. D., and H. K. were employees of Gr&#x000fc;nenthal GmbH at the time this work was conducted. K. K. and Mi. E. are employees of Janssen Research &#x00026; Development, LLC and Johnson &#x00026; Johnson stockholders</p></fn></fn-group></notes></front><body><sec id="ejp875-sec-0006"><label>1</label><title>Introduction</title><p>World Health Organization (WHO) step 2 analgesics, including the weak centrally acting analgesic tramadol, are often used for the management of moderate or moderate to severe, chronic cancer&#x02010;related pain (Leppert and Luczak, <xref rid="ejp875-bib-0008" ref-type="ref">2005</xref>; Vargas&#x02010;Schaffer, <xref rid="ejp875-bib-0012" ref-type="ref">2010</xref>). Tramadol, which has a favourable tolerability profile compared with strong classical opioid analgesics, is often initially preferred for patients with moderate to severe cancer&#x02010;related pain (Leppert and Luczak, <xref rid="ejp875-bib-0008" ref-type="ref">2005</xref>). When pain worsens, patients may need to be switched to a WHO step 3 analgesic (Vargas&#x02010;Schaffer, <xref rid="ejp875-bib-0012" ref-type="ref">2010</xref>). Strong classical opioid (WHO step 3) analgesics, such as morphine, may be associated with poor tolerability (Droney and Riley, <xref rid="ejp875-bib-0002" ref-type="ref">2009</xref>). Tapentadol prolonged release (PR), a centrally acting WHO step 3 analgesic with two mechanisms of action [&#x003bc;&#x02010;opioid receptor agonism and noradrenaline reuptake inhibition (Tzschentke et&#x000a0;al., <xref rid="ejp875-bib-0010" ref-type="ref">2006</xref>, <xref rid="ejp875-bib-0011" ref-type="ref">2009</xref>; Kress, <xref rid="ejp875-bib-0006" ref-type="ref">2010</xref>)], has been shown to be effective and well tolerated for the management of moderate to severe, chronic malignant tumour&#x02010;related pain (Imanaka et&#x000a0;al., <xref rid="ejp875-bib-0004" ref-type="ref">2013</xref>, <xref rid="ejp875-bib-0005" ref-type="ref">2014</xref>; Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>), with improved gastrointestinal tolerability compared with morphine controlled release (CR) (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>) and oxycodone CR (Imanaka et&#x000a0;al., <xref rid="ejp875-bib-0004" ref-type="ref">2013</xref>). Results of a recent, randomized&#x02010;withdrawal, parallel&#x02010;group, active&#x02010; and placebo&#x02010;controlled, double&#x02010;blind phase 3 study (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>) (ClinicalTrials.gov Identifier: NCT00472303) showed that tapentadol PR (100&#x02013;250&#x000a0;mg bid) was effective for the management of moderate to severe, chronic cancer pain with non&#x02010;inferior analgesic efficacy to that of morphine CR (40&#x02013;100&#x000a0;mg bid). Because of the randomized&#x02010;withdrawal design of the maintenance period for that study, the non&#x02010;inferiority comparison was limited to the 2&#x02010;week titration period (a potential limitation of the results) (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>). In that study, tapentadol PR was associated with lower incidences of overall side effects and gastrointestinal side effects than morphine CR during the titration period (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>). The current analysis of data from that phase 3 study evaluated the efficacy and tolerability of tapentadol PR in a subgroup of patients who had previously received tramadol and had converted directly to tapentadol PR treatment for the 2&#x02010;week titration period.</p></sec><sec id="ejp875-sec-0007"><label>2</label><title>Methods</title><sec id="ejp875-sec-0008"><label>2.1</label><title>Patients and study design</title><p>The multicentre, controlled, double&#x02010;blind phase 3 study (NCT00472303) included a screening period lasting up to 7&#x000a0;days, a 2&#x02010;week titration period and a 4&#x02010;week maintenance period. Details of the patient selection, study design and analyses for the full study population have been published previously (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>). Briefly summarized, the study included adult patients with moderate to severe, chronic, malignant tumour&#x02010;related pain [pain intensity &#x02265;5 on an 11&#x02010;point numerical rating scale (NRS) under their prior analgesic regimen at the start of titration, including tramadol or other opioids], who were opioid naive or dissatisfied with their current analgesic treatment (doses of tramadol or other opioids equivalent to oral morphine &#x02264;160&#x000a0;mg/day).</p><p>The study included an initial screening period of up to 7&#x000a0;days duration, during which patients could continue taking their previous analgesic (e.g. tramadol) treatment. Starting on the day of randomization, which immediately followed the screening period, patients were not permitted to take any analgesics other than the study drug (tapentadol PR or morphine CR) and morphine immediate release (IR) tablets as rescue medication as needed. Eligible patients were randomized (2:1) and titrated in a double&#x02010;blind manner to their optimal dose of tapentadol PR (100&#x02013;250&#x000a0;mg bid) or morphine sulphate CR (40&#x02013;100&#x000a0;mg bid) over 2&#x000a0;weeks. During stepwise titration, oral morphine sulphate IR 10&#x000a0;mg was permitted as rescue medication as needed (no maximum dose). Patients in the tapentadol PR titration group who met the prespecified response criteria that were published previously (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>) (and are described below under <italic>Study evaluations and statistical analyses</italic>) were re&#x02010;randomized to tapentadol PR or placebo bid in a double&#x02010;blind manner for a 4&#x02010;week maintenance period. Patients in the morphine CR titration group continued to receive morphine CR during the 4&#x02010;week maintenance period; these patients were not included in the present post hoc analysis. Thus, the present report will focus only on results for patients randomized to tapentadol PR after having been on tramadol treatment prior to randomization in the study.</p></sec><sec id="ejp875-sec-0009"><label>2.2</label><title>Study evaluations and statistical analyses</title><p>Only data collected during the tapentadol PR titration period (immediately after switching from tramadol to tapentadol PR) were evaluated for this subgroup of patients pretreated with any formulation of tramadol. Current pain intensity and average daily pain intensity at baseline of the titration period, Week 1, and Week 2, along with changes from baseline, were analysed. Pain intensity was evaluated using observed&#x02010;case analysis and the last observation carried forward (LOCF), baseline observation carried forward (BOCF) and worst observation carried forward (WOCF) for imputing missing values. Responder rates were also evaluated for the titration period. A responder was defined as a patient who completed the titration period, had a mean pain intensity score &#x0003c;5 (11&#x02010;point NRS; patient self&#x02010;recorded twice daily) during the last 3&#x000a0;days of titration and had a mean&#x000a0;dose of consumption of rescue medication &#x02264;20&#x000a0;mg/day during the last 3&#x000a0;days of titration. Treatment exposure and rescue medication use are summarized using descriptive statistics and frequency counts. Incidences of treatment&#x02010;emergent adverse events (TEAEs) were measured using frequency counts. The full analysis population for the titration period (all patients who received &#x02265;1 dose of study drug during the titration period) was used for all analyses. Results for this subgroup of patients who had received prior tramadol treatment were compared with those of the overall population of patients receiving tapentadol PR. No formal statistical analyses were performed to compare the data for the subgroup who had received prior tramadol treatment and the data for the overall population of patients receiving tapentadol PR. Formal statistical testing between the overall population of patients receiving tapentadol PR and the subgroup was not considered statistically valid because these were not independent populations of patients (i.e. the subgroup of patients receiving tramadol prior to tapentadol treatment was also included in the overall population), and also because this subgroup analysis was not powered or prespecified for comparison to the main population in this study.</p></sec></sec><sec id="ejp875-sec-0010"><label>3</label><title>Results</title><sec id="ejp875-sec-0011"><label>3.1</label><title>Patients and treatment exposure</title><p>Overall, 338 patients were randomized to and received treatment with tapentadol PR during the titration period (overall tapentadol PR group), whereas a subgroup of 129 of those patients had received prior therapy with tramadol within 3&#x000a0;days before randomization to tapentadol PR (tramadol/tapentadol PR subgroup). Demographic and baseline characteristics were comparable for patients in the tramadol/tapentadol PR subgroup and the overall tapentadol PR group (Table&#x000a0;<xref rid="ejp875-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="ejp875-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and baseline characteristics (full analysis population titration for tramadol/tapentadol PR subgroup; safety population titration for overall tapentadol PR group).<xref ref-type="fn" rid="ejp875-note-0004">a</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="char" valign="top" rowspan="1" colspan="1">Tramadol/tapentadol PR subgroup (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="char" valign="top" rowspan="1" colspan="1">Overall tapentadol PR group (<italic>n</italic>&#x000a0;=&#x000a0;338)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean (SD) age</td><td align="char" char=" " rowspan="1" colspan="1">60.9 (10.73)</td><td align="char" char=" " rowspan="1" colspan="1">59.8 (10.39)</td></tr><tr><td align="left" colspan="3" rowspan="1">Age category, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">79 (61.2)</td><td align="char" char=" " rowspan="1" colspan="1">224 (66.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">50 (38.8)</td><td align="char" char=" " rowspan="1" colspan="1">114 (33.7)</td></tr><tr><td align="left" colspan="3" rowspan="1">Gender, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="char" char=" " rowspan="1" colspan="1">70 (54.3)</td><td align="char" char=" " rowspan="1" colspan="1">188 (55.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="char" char=" " rowspan="1" colspan="1">59 (45.7)</td><td align="char" char=" " rowspan="1" colspan="1">150 (44.4)</td></tr><tr><td align="left" colspan="3" rowspan="1">Race, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="char" char=" " rowspan="1" colspan="1">129 (100)</td><td align="char" char=" " rowspan="1" colspan="1">338 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) BMI, kg/m<sup>2</sup>
</td><td align="char" char=" " rowspan="1" colspan="1">24.6 (5.12)</td><td align="char" char=" " rowspan="1" colspan="1">25.0 (5.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuropathic pain present, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">84 (65.1)</td><td align="char" char=" " rowspan="1" colspan="1">222 (65.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Visceral pain present, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">65 (50.4)</td><td align="char" char=" " rowspan="1" colspan="1">166 (49.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nociceptive pain present, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">85 (65.9)</td><td align="char" char=" " rowspan="1" colspan="1">236 (69.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior opioid treatment received, <italic>n</italic> (%)</td><td align="char" char=" " rowspan="1" colspan="1">129 (100)</td><td align="char" char=" " rowspan="1" colspan="1">298 (88.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD) baseline pain intensity<xref ref-type="fn" rid="ejp875-note-0005">b</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">6.4 (1.31)</td><td align="char" char=" " rowspan="1" colspan="1">6.4 (1.46)</td></tr></tbody></table><table-wrap-foot><fn id="ejp875-note-0003"><p>PR, prolonged release; SD, standard deviation; BMI, body mass index; NRS, numerical rating scale.</p></fn><fn id="ejp875-note-0004"><label>a</label><p>For the tramadol/tapentadol PR subgroup, the full analysis population for the titration period is the same as the safety population for the titration period.</p></fn><fn id="ejp875-note-0005"><label>b</label><p>Pain intensity was rated on an 11&#x02010;point NRS (0&#x000a0;=&#x000a0;&#x0201c;no pain&#x0201d; to 10&#x000a0;=&#x000a0;&#x0201c;pain as bad as you can imagine&#x0201d;).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Tramadol was the most frequently used centrally acting analgesic prior to initiating study treatment with tapentadol PR; 46.2% (156/338) of patients in the tapentadol PR group had taken tramadol at any time during the 30&#x000a0;days prior to the start of the study. The most common classical opioid analgesics taken during the 30&#x000a0;days prior to starting tapentadol PR treatment by &#x02265;5% of patients were morphine [19.5% (66/338)], fentanyl [20.4% (69/338)], oxycodone [7.4% (25/338)], hydromorphone [6.2% (21/338)] and dihydrocodeine [5.6% (19/338)]. Patients may have been taking &#x02265;1 opioid concomitantly prior to entering the study.</p><p>The percentage of patients who discontinued treatment during the titration period was comparable in the tramadol/tapentadol PR subgroup and the overall tapentadol PR group, as were the reasons for discontinuation (Table&#x000a0;<xref rid="ejp875-tbl-0002" ref-type="table-wrap">2</xref>). The mean daily dose and mean modal dose of tapentadol PR during the titration period were similar in the tramadol/tapentadol PR subgroup and overall tapentadol PR group (Table&#x000a0;<xref rid="ejp875-tbl-0003" ref-type="table-wrap">3</xref>). The mean duration of exposure to tapentadol PR was approximately 13&#x000a0;days in both the tramadol/tapentadol PR subgroup and the overall tapentadol PR group (Table&#x000a0;<xref rid="ejp875-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="ejp875-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Reasons for treatment discontinuation during the titration period (full analysis population titration for tramadol/tapentadol PR subgroup; safety population titration for overall tapentadol PR group).<xref ref-type="fn" rid="ejp875-note-0007">a</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Reason for discontinuation, <italic>n</italic> (%)</th><th align="char" valign="top" rowspan="1" colspan="1">Tramadol/tapentadol PR subgroup (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="char" valign="top" rowspan="1" colspan="1">Overall tapentadol PR group (<italic>n</italic>&#x000a0;=&#x000a0;338)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Discontinued for any reason</td><td align="char" char=" " rowspan="1" colspan="1">20 (15.5)</td><td align="char" char=" " rowspan="1" colspan="1">59 (17.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Adverse events</td><td align="char" char=" " rowspan="1" colspan="1">5 (3.9)</td><td align="char" char=" " rowspan="1" colspan="1">22 (6.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Patient choice (withdrawal of consent)</td><td align="char" char=" " rowspan="1" colspan="1">8 (6.2)</td><td align="char" char=" " rowspan="1" colspan="1">16 (4.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Death</td><td align="char" char=" " rowspan="1" colspan="1">2 (1.6)</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lack of efficacy</td><td align="char" char=" " rowspan="1" colspan="1">2 (1.6)</td><td align="char" char=" " rowspan="1" colspan="1">10 (3.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Study drug non&#x02010;compliant</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.8)</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="char" char=" " rowspan="1" colspan="1">2 (1.6)</td><td align="char" char=" " rowspan="1" colspan="1">3 (0.9)</td></tr></tbody></table><table-wrap-foot><fn id="ejp875-note-0006"><p>PR, prolonged release.</p></fn><fn id="ejp875-note-0007"><label>a</label><p>For the tramadol/tapentadol PR subgroup, the full analysis population for the titration period was the same as the safety population for the titration period.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="ejp875-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Dose and duration of exposure to tapentadol PR (full analysis population titration for tramadol/tapentadol PR subgroup; safety population titration for overall tapentadol PR group).<xref ref-type="fn" rid="ejp875-note-0009">a</xref>
<sup>,</sup>
<xref ref-type="fn" rid="ejp875-note-0010">b</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="char" valign="top" rowspan="1" colspan="1">Tramadol/tapentadol PR subgroup (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="char" valign="top" rowspan="1" colspan="1">Overall tapentadol PR group (<italic>n</italic>&#x000a0;=&#x000a0;338)</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Mean daily dose, mg</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td><td align="char" char=" " rowspan="1" colspan="1">264.5 (63.58)</td><td align="char" char=" " rowspan="1" colspan="1">276.1 (66.66)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (range)</td><td align="char" char=" " rowspan="1" colspan="1">264.3 (150, 382)</td><td align="char" char=" " rowspan="1" colspan="1">278.6 (100, 386)</td></tr><tr><td align="left" colspan="3" rowspan="1">Modal dose,<xref ref-type="fn" rid="ejp875-note-0011">c</xref> mg</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td><td align="char" char=" " rowspan="1" colspan="1">284.5 (101.13)</td><td align="char" char=" " rowspan="1" colspan="1">302.7 (107.56)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (range)</td><td align="char" char=" " rowspan="1" colspan="1">300 (100, 500)</td><td align="char" char=" " rowspan="1" colspan="1">300 (100, 500)</td></tr><tr><td align="left" colspan="3" rowspan="1">Total duration, days</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean (SD)</td><td align="char" char=" " rowspan="1" colspan="1">13.2 (2.90)</td><td align="char" char=" " rowspan="1" colspan="1">13.0 (3.09)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (range)</td><td align="char" char=" " rowspan="1" colspan="1">14 (2, 18)</td><td align="char" char=" " rowspan="1" colspan="1">14 (2, 18)</td></tr><tr><td align="left" style="padding-left:10%" colspan="3" rowspan="1">Category, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02264;7&#x000a0;days</td><td align="char" char=" " rowspan="1" colspan="1">10 (7.8)</td><td align="char" char=" " rowspan="1" colspan="1">32 (9.5)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">8&#x02013;14&#x000a0;days</td><td align="char" char=" " rowspan="1" colspan="1">92 (71.3)</td><td align="char" char=" " rowspan="1" colspan="1">235 (69.5)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;15&#x000a0;days</td><td align="char" char=" " rowspan="1" colspan="1">27 (20.9)</td><td align="char" char=" " rowspan="1" colspan="1">71 (21.0)</td></tr></tbody></table><table-wrap-foot><fn id="ejp875-note-0008"><p>PR, prolonged release; SD, standard deviation.</p></fn><fn id="ejp875-note-0009"><label>a</label><p>For the tramadol/tapentadol PR subgroup, the full analysis population for the titration period is the same as the safety population for the titration period.</p></fn><fn id="ejp875-note-0010"><label>b</label><p>Data shown are only for the titration period.</p></fn><fn id="ejp875-note-0011"><label>c</label><p>Tramadol/tapentadol PR subgroup, <italic>n</italic>&#x000a0;=&#x000a0;129; overall tapentadol PR group, <italic>n</italic>&#x000a0;=&#x000a0;337.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="ejp875-sec-0012"><label>3.2</label><title>Efficacy</title><p>During the titration period (Supporting Information Table&#x000a0;S1), the mean [standard deviation (SD)] decreases in average current pain intensity from baseline to Week 1 and from baseline to Week 2 of titration (LOCF) were comparable in the tramadol/tapentadol PR subgroup [mean (SD) change: baseline to Week 1, &#x02212;1.4 (1.56); baseline to Week 2, &#x02212;2.4 (2.01)] and the overall tapentadol PR group [&#x02212;1.0 (1.58) and &#x02212;2.1 (2.05), respectively]. Mean (SD) decreases in average daily pain intensity during the titration period (LOCF) were also comparable in the tramadol/tapentadol PR subgroup [mean (SD) change: baseline to Week 1, &#x02212;1.3 (1.50); baseline to Week 2, &#x02212;2.1 (1.90)] and the overall tapentadol PR group [&#x02212;1.0 (1.51) and &#x02212;2.0 (1.95), respectively]. Similar decreases in average current pain intensity and average daily pain intensity during the titration period were observed in each of the treatment groups with observed&#x02010;case analysis, BOCF and WOCF, and these decreases were generally comparable in the tramadol/tapentadol PR subgroup and the overall tapentadol PR group (Supporting Information Table&#x000a0;S1).</p><p>Response rates during the titration period were high and similar in both the tramadol/tapentadol PR subgroup [69.8% (90/129)] and in the overall tapentadol PR group [63.9% (214/335)]. The most common reason for non&#x02010;response during the titration period was an average pain intensity &#x02265;5 during the last 3&#x000a0;days of the titration period [tramadol/tapentadol PR subgroup, 6.2% (8/129); overall tapentadol PR group, 9.9% (33/335)].</p><p>A similar percentage of patients used rescue medication in the tramadol/tapentadol PR subgroup [70.5% (91/129)] and in the overall tapentadol PR group [71.9% (241/335)]. The mean (SD) total daily dose of rescue medication was comparable in the tramadol/tapentadol PR subgroup [12.0 (16.87) mg] and in the overall tapentadol PR group [13.3 (17.41) mg], as was the mean (SD) percent of days with rescue medication use [45.1% (39.44%) vs. 46.3% (39.69%), respectively].</p></sec><sec id="ejp875-sec-0013"><label>3.3</label><title>Safety and tolerability</title><p>During the titration period, 50.4% (65/129) of patients in the tramadol/tapentadol PR subgroup and 50.0% (169/338) of patients in the overall tapentadol PR group reported &#x02265;1 TEAE. Gastrointestinal and nervous system TEAEs were the most commonly reported TEAEs (incidence &#x02265;5%) during the titration period, and incidences of these TEAEs were generally comparable in the tramadol/tapentadol PR subgroup and in the overall tapentadol PR group (Table&#x000a0;<xref rid="ejp875-tbl-0004" ref-type="table-wrap">4</xref>).</p><table-wrap id="ejp875-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Individual TEAEs reported for &#x02265;5% of patients in the tramadol/tapentadol PR subgroup or the overall tapentadol PR group during the titration period (safety populations titration)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">System organ class, <italic>n</italic> (%) TEAE, <italic>n</italic> (%)</th><th align="char" valign="top" rowspan="1" colspan="1">Tramadol/tapentadol PR subgroup (<italic>n</italic>&#x000a0;=&#x000a0;129)</th><th align="char" valign="top" rowspan="1" colspan="1">Overall tapentadol PR group (<italic>n</italic>&#x000a0;=&#x000a0;338)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gastrointestinal disorders</td><td align="char" char=" " rowspan="1" colspan="1">39 (30.2)</td><td align="char" char=" " rowspan="1" colspan="1">100 (29.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Constipation</td><td align="char" char=" " rowspan="1" colspan="1">20 (15.5)</td><td align="char" char=" " rowspan="1" colspan="1">48 (14.2)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nausea</td><td align="char" char=" " rowspan="1" colspan="1">13 (10.1)</td><td align="char" char=" " rowspan="1" colspan="1">42 (12.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vomiting</td><td align="char" char=" " rowspan="1" colspan="1">5 (3.9)</td><td align="char" char=" " rowspan="1" colspan="1">18 (5.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nervous system disorders</td><td align="char" char=" " rowspan="1" colspan="1">21 (16.3)</td><td align="char" char=" " rowspan="1" colspan="1">46 (13.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Somnolence</td><td align="char" char=" " rowspan="1" colspan="1">9 (7.0)</td><td align="char" char=" " rowspan="1" colspan="1">14 (4.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dizziness</td><td align="char" char=" " rowspan="1" colspan="1">8 (6.2)</td><td align="char" char=" " rowspan="1" colspan="1">17 (5.0)</td></tr></tbody></table><table-wrap-foot><fn id="ejp875-note-0012"><p>TEAE, treatment&#x02010;emergent adverse event; PR, prolonged release.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="ejp875-sec-0014"><label>4</label><title>Discussion and conclusions</title><p>Opioid analgesics have an established role in the management of moderate to severe cancer pain (Droney and Riley, <xref rid="ejp875-bib-0002" ref-type="ref">2009</xref>; Caraceni et&#x000a0;al., <xref rid="ejp875-bib-0001" ref-type="ref">2012</xref>). Morphine has typically been considered the first&#x02010;line analgesic option for patients with moderate to severe cancer pain (Droney and Riley, <xref rid="ejp875-bib-0002" ref-type="ref">2009</xref>; Caraceni et&#x000a0;al., <xref rid="ejp875-bib-0001" ref-type="ref">2012</xref>) and, along with other opioid analgesics, has a long&#x02010;standing history of clinical use for cancer pain management (Droney and Riley, <xref rid="ejp875-bib-0002" ref-type="ref">2009</xref>; Caraceni et&#x000a0;al., <xref rid="ejp875-bib-0001" ref-type="ref">2012</xref>). Morphine and other opioids are often associated with poor, particularly gastrointestinal, tolerability in patients with cancer pain (Droney and Riley, <xref rid="ejp875-bib-0002" ref-type="ref">2009</xref>), and opioid&#x02010;induced gastrointestinal side effects may prove particularly problematic for these patients (Mandala et&#x000a0;al., <xref rid="ejp875-bib-0009" ref-type="ref">2006</xref>; Droney et&#x000a0;al., <xref rid="ejp875-bib-0003" ref-type="ref">2008</xref>; Caraceni et&#x000a0;al., <xref rid="ejp875-bib-0001" ref-type="ref">2012</xref>). In patients who need to switch from a WHO step 2 (e.g. tramadol) to a WHO step 3 analgesic due to worsening pain, tapentadol PR, which has demonstrated improved gastrointestinal tolerability compared with morphine CR (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>) and oxycodone CR (Imanaka et&#x000a0;al., <xref rid="ejp875-bib-0004" ref-type="ref">2013</xref>) in cancer pain patients, may be a favourable option.</p><p>In this phase 3 cancer pain study, the majority of patients who were pretreated with the WHO step 2 analgesic tramadol before randomization, who were dissatisfied with that treatment for any reason, and who had a pain intensity score &#x02265;5 (11&#x02010;point NRS) experienced improvements in efficacy after switching to the WHO step 3 analgesic tapentadol PR (100&#x02013;250&#x000a0;mg bid). Responder rates during the titration period for this subgroup of patients who were pretreated with the WHO step 2 opioid tramadol were high (approximately 70%), and the tolerability profile was similar to the&#x000a0;overall tapentadol PR group. Thus, based on the responder criteria, the majority of tramadol&#x02010;pretreated patients were able to complete treatment with tapentadol PR during the titration period and experienced a reduction in pain intensity to &#x0003c;5 by the end of the titration period, without the need for excessive rescue medication.</p><p>Analgesic efficacy during the titration period for this subgroup of tramadol&#x02010;pretreated patients who switched to tapentadol PR was generally comparable to that for the overall population of patients who received tapentadol PR during the titration period of the randomized, controlled phase 3 study (Kress et&#x000a0;al., <xref rid="ejp875-bib-0007" ref-type="ref">2014</xref>). On average, doses of tapentadol PR used in the tramadol/tapentadol PR subgroup were comparable to those used in the overall tapentadol PR group. Importantly, tapentadol PR was generally well tolerated in this subgroup of patients switching from tramadol (a WHO step 2 opioid) to tapentadol PR (a WHO step 3 analgesic), with a similar tolerability profile to the overall tapentadol PR group during titration. These results indicate that efficacy and tolerability were similar for a subgroup of patients who were pretreated with tramadol prior to randomization to tapentadol and the overall tapentadol PR group. It should be noted that comparisons between the tramadol/tapentadol PR subgroup and overall tapentadol PR group were descriptive. No formal statistical analyses were performed to compare the data for the tramadol/tapentadol PR subgroup and the overall tapentadol PR group.</p><p>Results of this present subgroup analysis suggest that patients who need to switch from the WHO step 2 analgesic tramadol for any reason (e.g. inadequate pain relief) can safely be converted directly to the WHO step 3 analgesic tapentadol PR for improved analgesic therapy for severe pain.</p></sec><sec id="ejp875-sec-0015"><title>Author contributions</title><p>H.G.K. served as international study coordinator and principal investigator, and was involved in developing research questions and study design. A.S. was involved in the planning and review of additional analyses. K.K. performed the statistical analyses. All authors contributed to the interpretation of the data, discussed the results, critically reviewed and commented on the manuscript and approved the final version submitted for publication.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;S1.</bold> Average pain intensity scores during the titration period and change in average pain intensity from the start of titration (full analysis populations&#x02010;titration).</p></caption><media xlink:href="EJP-20-1513-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ejp875-sec-0016"><title>Acknowledgements</title><p>These analyses were funded by Gr&#x000fc;nenthal GmbH and Janssen Research &#x00026; Development, LLC. Editorial support for the writing of this manuscript was provided by Megan Knagge, PhD, of MedErgy, and was funded by Gr&#x000fc;nenthal GmbH and Janssen Research &#x00026; Development, LLC.</p></ack><ref-list content-type="cited-references" id="ejp875-bibl-0001"><title>References</title><ref id="ejp875-bib-0001"><mixed-citation publication-type="journal" id="ejp875-cit-0001">
<string-name>
<surname>Caraceni</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hanks</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Kaasa</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>, <given-names>M.I.</given-names>
</string-name>, <string-name>
<surname>Brunelli</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Cherny</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Dale</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>De Conno</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Fallon</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hanna</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Haugen</surname>, <given-names>D.F.</given-names>
</string-name>, <string-name>
<surname>Juhl</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>King</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Klepstad</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Laugsand</surname>, <given-names>E.A.</given-names>
</string-name>, <string-name>
<surname>Maltoni</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mercadante</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Nabal</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pigni</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Radbruch</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Reid</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Sjogren</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Stone</surname>, <given-names>P.C.</given-names>
</string-name>, <string-name>
<surname>Tassinari</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Zeppetella</surname>, <given-names>G.</given-names>
</string-name> (<year>2012</year>). <article-title>Use of opioid analgesics in the treatment of cancer pain: Evidence&#x02010;based recommendations from the EAPC</article-title>. <source>Lancet Oncol</source>
<volume>13</volume>, <fpage>e58</fpage>&#x02013;<lpage>e68</lpage>.<pub-id pub-id-type="pmid">22300860</pub-id></mixed-citation></ref><ref id="ejp875-bib-0002"><mixed-citation publication-type="journal" id="ejp875-cit-0002">
<string-name>
<surname>Droney</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Riley</surname>, <given-names>J.</given-names>
</string-name> (<year>2009</year>). <article-title>Recent advances in the use of opioids for cancer pain</article-title>. <source>J Pain Res</source>
<volume>2</volume>, <fpage>135</fpage>&#x02013;<lpage>155</lpage>.<pub-id pub-id-type="pmid">21197301</pub-id></mixed-citation></ref><ref id="ejp875-bib-0003"><mixed-citation publication-type="journal" id="ejp875-cit-0003">
<string-name>
<surname>Droney</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ross</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Gretton</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Welsh</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sato</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Riley</surname>, <given-names>J.</given-names>
</string-name> (<year>2008</year>). <article-title>Constipation in cancer patients on morphine</article-title>. <source>Support Care Cancer</source>
<volume>16</volume>, <fpage>453</fpage>&#x02013;<lpage>459</lpage>.<pub-id pub-id-type="pmid">18197439</pub-id></mixed-citation></ref><ref id="ejp875-bib-0004"><mixed-citation publication-type="journal" id="ejp875-cit-0004">
<string-name>
<surname>Imanaka</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Tominaga</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Etropolski</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Van Hove</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Ohsaka</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wanibe</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hirose</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Matsumura</surname>, <given-names>T.</given-names>
</string-name> (<year>2013</year>). <article-title>Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor&#x02010;related pain</article-title>. <source>Curr Med Res Opin</source>
<volume>29</volume>, <fpage>1399</fpage>&#x02013;<lpage>1409</lpage>.<pub-id pub-id-type="pmid">23937387</pub-id></mixed-citation></ref><ref id="ejp875-bib-0005"><mixed-citation publication-type="journal" id="ejp875-cit-0005">
<string-name>
<surname>Imanaka</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Tominaga</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Etropolski</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ohashi</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Hirose</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Matsumura</surname>, <given-names>T.</given-names>
</string-name> (<year>2014</year>). <article-title>Ready conversion of patients with well&#x02010;controlled, moderate to severe, chronic malignant tumor&#x02010;related pain on other opioids to tapentadol extended release</article-title>. <source>Clin Drug Investig</source>
<volume>34</volume>, <fpage>501</fpage>&#x02013;<lpage>511</lpage>.</mixed-citation></ref><ref id="ejp875-bib-0006"><mixed-citation publication-type="journal" id="ejp875-cit-0006">
<string-name>
<surname>Kress</surname>, <given-names>H.G.</given-names>
</string-name> (<year>2010</year>). <article-title>Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally&#x02010;acting analgesics on the horizon?</article-title>
<source>Eur J Pain</source>
<volume>14</volume>, <fpage>781</fpage>&#x02013;<lpage>783</lpage>.<pub-id pub-id-type="pmid">20659810</pub-id></mixed-citation></ref><ref id="ejp875-bib-0007"><mixed-citation publication-type="journal" id="ejp875-cit-0007">
<string-name>
<surname>Kress</surname>, <given-names>H.G.</given-names>
</string-name>, <string-name>
<surname>Koch</surname>, <given-names>E.D.</given-names>
</string-name>, <string-name>
<surname>Kosturski</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Steup</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Karcher</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Lange</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Dogan</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Etropolski</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Eerdekens</surname>, <given-names>M.</given-names>
</string-name> (<year>2014</year>). <article-title>Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor&#x02010;related pain</article-title>. <source>Pain Physician</source>
<volume>17</volume>, <fpage>329</fpage>&#x02013;<lpage>343</lpage>.<pub-id pub-id-type="pmid">25054392</pub-id></mixed-citation></ref><ref id="ejp875-bib-0008"><mixed-citation publication-type="journal" id="ejp875-cit-0008">
<string-name>
<surname>Leppert</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Luczak</surname>, <given-names>J.</given-names>
</string-name> (<year>2005</year>). <article-title>The role of tramadol in cancer pain treatment &#x02013; A review</article-title>. <source>Support Care Cancer</source>
<volume>13</volume>, <fpage>5</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">15668743</pub-id></mixed-citation></ref><ref id="ejp875-bib-0009"><mixed-citation publication-type="journal" id="ejp875-cit-0009">
<string-name>
<surname>Mandala</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Moro</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Labianca</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Cremonesi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Barni</surname>, <given-names>S.</given-names>
</string-name> (<year>2006</year>). <article-title>Optimizing use of opiates in the management of cancer pain</article-title>. <source>Ther Clin Risk Manag</source>
<volume>2</volume>, <fpage>447</fpage>&#x02013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">18360655</pub-id></mixed-citation></ref><ref id="ejp875-bib-0010"><mixed-citation publication-type="journal" id="ejp875-cit-0010">
<string-name>
<surname>Tzschentke</surname>, <given-names>T.M.</given-names>
</string-name>, <string-name>
<surname>De Vry</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Terlinden</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Hennies</surname>, <given-names>H.H.</given-names>
</string-name>, <string-name>
<surname>Lange</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Strassburger</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Haurand</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kolb</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Buschmann</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Finkam</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Jahnel</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Friderichs</surname>, <given-names>E.</given-names>
</string-name> (<year>2006</year>). <article-title>Tapentadol hydrochloride. Analgesic, mu&#x02010;opioid receptor agonist, noradrenaline reuptake inhibitor</article-title>. <source>Drugs Future</source>
<volume>31</volume>, <fpage>1053</fpage>&#x02013;<lpage>1061</lpage>.</mixed-citation></ref><ref id="ejp875-bib-0011"><mixed-citation publication-type="journal" id="ejp875-cit-0011">
<string-name>
<surname>Tzschentke</surname>, <given-names>T.M.</given-names>
</string-name>, <string-name>
<surname>Jahnel</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Kogel</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Christoph</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Englberger</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>De Vry</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schiene</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Upmalis</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Weber</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Lange</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Stegmann</surname>, <given-names>J.U.</given-names>
</string-name>, <string-name>
<surname>Kleinert</surname>, <given-names>R.</given-names>
</string-name> (<year>2009</year>). <article-title>Tapentadol hydrochloride: A next&#x02010;generation, centrally acting analgesic with two mechanisms of action in a single molecule</article-title>. <source>Drugs Today (Barc)</source>
<volume>45</volume>, <fpage>483</fpage>&#x02013;<lpage>496</lpage>.<pub-id pub-id-type="pmid">19834626</pub-id></mixed-citation></ref><ref id="ejp875-bib-0012"><mixed-citation publication-type="journal" id="ejp875-cit-0012">
<string-name>
<surname>Vargas&#x02010;Schaffer</surname>, <given-names>G.</given-names>
</string-name> (<year>2010</year>). <article-title>Is the WHO analgesic ladder still valid? Twenty&#x02010;four years of experience</article-title>. <source>Can Fam Physician</source>
<volume>56</volume>, <fpage>514</fpage>&#x02013;<lpage>515</lpage>.<pub-id pub-id-type="pmid">20547511</pub-id></mixed-citation></ref></ref-list></back></article>